Market Research Logo

U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 202

U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). The rising incidences of blood disorders and chronic diseases; rapid increase in the aging population; and increasing adoption of therapeutic plasma exchange in rare neurological, hematology, and autoimmune disorders are key factors driving the therapeutic plasma exchange market in the U.S. In this report, the market is segmented by indication, number of patients, and total number of TPE procedures performed by indication.

Therapeutic plasma exchange removes plasma components from blood. A blood cell separator extracts the patient’s plasma and returns red blood cells (RBCs) and platelets in plasma or a plasma-replacing fluid; for this purpose, 5% albumin is preferred to fresh frozen plasma (except for patients with thrombotic thrombocytopenic purpura) because it causes fewer reactions and transmits no infections. Therapeutic plasma exchange resembles dialysis but, in addition, can remove protein-bound toxic substances. A one-volume exchange removes about 66% of such components. Due to this factor, the awareness among physicians is growing, hence therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases such as Guillain-Barré syndrome, thrombotic thrombocytopenic purpura (TTP), Goodpasture syndrome, and Wegener’s Granulomatosis. This trend is expected to continue in the coming years as well.

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. TPE market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market diversification, and competitive assessment) for reaping greater market shares.

This report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the therapeutic plasma exchange market. The report analyzes the therapeutic plasma exchange market by indication, total number of TPE procedures performed, and number of patients treated with TPE in the U.S.
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and new product launches in the therapeutic plasma exchange market
Market Diversification: Exhaustive information about new products, major product segments and indications, recent developments, and investments in the therapeutic plasma exchange market
Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and product portfolio and pricing analyses of the leading players in the therapeutic plasma exchange market


  • INTRODUCTION
    • OBJECTIVES & SCOPE OF THE STUDY
    • RESEARCH METHODOLOGY
    • MARKET ESTIMATION METHODOLOGY
    • DATA MODEL
      • Table DATA MODEL
    • SECONDARY SOURCES
    • PRIMARY RESEARCH METHODOLOGY
    • PRIMARY RESPONDENT PROFILE
    • LIST OF ORGANIZATIONS CONTACTED
  • KEY INSIGHTS
    • U.S. THERAPEUTIC PLASMA EXCHANGE MARKET
      • Table U.S .: THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2014 14- 4-2021 (USD MILLION)
      • Table U.S .: THERAPEUTIC PLASMA EXCHANGE MARKET-PATIENT POPULATION AND NUMBER OF PROCEDURES
    • FACTORS AFFECTING MARKET GROWTH
  • Therapeutic Plasma Exchange Market, by Indication
    • GUILLAIN-BARRÉ SYNDROME (GBS)
      • Table U.S. DISEASE STATISTICS: ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY
      • Table TREATMENT GUIDELINES & PROTOCOLS : GUILLAIN - BARRÉ SYNDROME (GBS)
      • Table EPIDEMIOLOG : GUILLAIN - BARRÉ SYNDROME (GBS)
    • CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
      • Table U.S . DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
      • Table TREATMEN GUIDELINES & PROTOCOLS : CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
      • Table EPIDEMIOLOGY : CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
    • MYASTHENIA GRAVIS (MG)
      • Table U.S. DISEASE STATISTICS: MYASTHENIA GRAVIS
      • Table TREATMEN GUIDELINES & PROTOCOLS : MYASTHENIA GRAVIS
      • Table EPIDEMIOLOGY: MYASTHENIA GRAVIS
    • MULTIPLE SCLEROSIS (MS)
      • Table U.S. DISEASE STATISTICS: MULTIPLE SCLEROSIS
      • Table TREATMEN GUIDELINES & PROTOCOLS : MULTIPLE SCLEROSIS
      • Table EPIDEMIOLOGY : MULTIPLE SCLEROSIS
    • NEUROMYELITIS OPTICA (NMO)
      • Table U.S . DISEASE STATISTICS: NEUROMYELITIS OPTICA
      • Table TREATMEN GUIDELINES & PROTOCOLS : NEUROMYELITIS OPTICA
      • Table EPIDEMIOLOGY : NEUROMYELITIS OPTICA
    • THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
      • Table U.S . DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA
      • Table TREATMEN GUIDELINES & PROTOCOLS : THROMBOTIC THROMBOCYTOPENIC PURPURA
      • Table EPIDEMIOLOGY : THROMBOTIC THROMBOCYTOPENIC PURPURA
    • CRYOGLOBULINEMIA
      • Table U.S . DISEASE STATISTICS: CRYOGLOBULINEMIA
      • Table TREATMEN GUIDELINES & PROTOCOLS : CRYOGLOBULINEMIA
      • Table EPIDEMIOLOGY : CRYOGLOBULINEMIA
    • MULTIPLE MYELOMA (MM)
      • Table U.S . DISEASE STATISTICS: MULTIPLE MYELOMA
      • Table TREATMEN GUIDELINES & PROTOCOLS : MULTIPLE MYELOMA
      • Table EPIDEMIOLOGY : MULTIPLE MYELOMA
    • WALDENSTROM MACROGLOBULINEMIA (WM)
      • Table U.S . DISEASE STATISTICS: WALDENSTROM MACROGLOBULINEMIA
      • Table TREATMEN GUIDELINES & PROTOCOLS : WALDENSTROM MACROGLOBULINEMIA
      • Table EPIDEMIOLOGY : WALDENSTROM MACROGLOBULINEMIA
    • HEMOLYTIC UREMIC SYNDROME (HUS)
      • Table U.S . DISEASE STATISTICS: HEMOLYTIC UREMIC SYNDROME
      • Table TREATMEN GUIDELINES & PROTOCOLS : HEMOLYTIC UREMIC SYNDROME
      • Table EPIDEMIOLOGY : HEMOLYTIC UREMIC SYNDROME
    • ANTI-GBM DISEASE (GOODPASTURE'S SYNDROME)
      • Table U.S. DISEASE STATISTICS: ANTI - GBM DISEASE (GOODPASTURE'S SYNDROME)
      • Table TREATMEN GUIDELINES & PROTOCOLS : ANTI - GBM DISEASE (GOODPASTURE'S SYNDROME)
      • Table EPIDEMIOLOGY : ANTI - GBM DISEASE (GOODPASTURE'S SYNDROME)
    • WEGENER'S GRANULOMATOSIS (ANCA-ASSOCIATED RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS)
      • Table U.S . DISEASE STATISTICS: WEGENER'S GRANULOMATOSIS
      • Table TREATMEN GUIDELINES & PROTOCOLS : WEGENER'S GRANULOMATOSIS
      • Table EPIDEMIOLOGY : WEGENER'S GRANULOMATOSIS
    • POST-RENAL TRANSPLANT REJECTION
      • Table U.S . DISEASE STATISTICS: POST - RENAL TRANSPLANT REJECTION
      • Table TREATMEN GUIDELINES & PROTOCOLS : POST - RENAL TRANSPLANT REJECTION
      • Table EPIDEMIOLOGY : POST - RENAL TRANSPLANT REJECTION
    • FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
      • Table U.S . DISEASE STATISTICS: FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
      • Table TREATMEN GUIDELINES & PROTOCOLS : FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
      • Table EPIDEMIOLOGY : FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
    • ANCA-ASSOCIATED VASCULITIS
      • Table U.S . DISEASE STATISTICS: ANCA - ASSOCIATED VASCULITIS
  • APPENDIX
    • EPIDEMIOLOGY DATA
      • Table EPIDEMIOLOGY DATA
    • INDUSTRY SPEAKS
    • DETAILS OF PRIMARY RESPONDENTS
      • Table DETAILS OF PRIMARY RESPONDENTS
    • AVAILABLE CUSTOMIZATIONS
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report